Page 1 - Dyslipidaemia_newsletter8_2024_Final
P. 1
REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #8 2024
TABLE OF CONTENTS
KEY ARTICLES Welcome back to the Reflections Dyslipidaemia Global Newsletter,
where an international Scientific Planning Committee summarizes
GUIDELINES AND REVIEWS and provides expert commentary on the latest clinical and real-
2024 ESC Guidelines for the management of chronic world evidence in the field of dyslipidaemia. These articles are
coronary syndromes. Vrints C, et al. Eur Heart J. 2024 Aug chosen based on their significance to every day clinical practice.
Dyslipida
30:ehae177. doi: 10.1093/eurheartj/ehae177. Online ahead of print. This newsletter focuses on the new 2024 ESC Guidelines for
Inflammation, cholesterol, lipoprotein(a), and 30-year CCS, along with a few interesting review articles on biomarkers
cardiovascular outcomes in women. Ridker PM, et al. N Engl and risks of CV, a real-world analysis of adherence and outcomes
J Med. 2024 Aug 31. doi: 10.1056/NEJMoa2405182. Online ahead
of print. in patients taking a single-pill combination vs. free combination
Lipoprotein(a) and cardiovascular disease. Nordestgaard of rosuvastatin and ezetimibe, a cohort study focused on
BG, Langsted A. Lancet. 2024 Sep 12:S0140-6736(24)01308-4. combination statin/ezetimibe vs. high-intensity statin monotherapy
on CV outcomes, and a clinical consensus statement from the
TREATMENT National Lipid Association focused on dyslipidaemia in women of
A real-world analysis of adherence, biochemical outcomes, reproductive age. We are also pleased to share our Conference
and healthcare costs in patients treated with rosuvastatin/ Corner, where we highlight some abstracts of interest from the
ezetimibe as single-pill combination vs. free combination recent 2024 ESC Congress which took place in London, England.
in Italy. Zambon A, et al. Eur Heart J Open. 2024 Aug As with the previous newsletters, we invite you to interact through
28;4(5):oeae074. links to short video commentaries from our SPC, links to videos
Combination of low- or moderate-intensity statin and or podcasts, along with hyperlinks to full articles for in-depth study
ezetimibe vs. high-intensity statin monotherapy on primary and reflection.
prevention of cardiovascular disease and all-cause death:
a propensity-matched nationwide cohort study. Jun JE, et al. Prof. Farnier (Chair)
Eur J Prev Cardiol. 2024 Aug 9;31(10):1205-1213.
SPECIAL POPULATIONS – WOMEN OF SCIENTIFIC PLANNING COMMITTEE
REPRODUCTIVE AGE
Dyslipidemia management in women of reproductive Prof. Michel Farnier Prof. Augusto Lavalle
potential: An expert clinical consensus from the national (France) Cobo
(Argentina)
lipid association. Agarwala A, et al. J Clin Lipidol. 2024 May
30:S1933-2874(24)00188-0.
Prof. Miriam Sandin Prof. Lourdes Santos
ADDITIONAL ARTICLES OF INTEREST (Spain) (Philippines)
CONFERENCE CORNER
Highlighted abstracts of interest from the ESC 2024
conference Prof. Ahmed Shawky Prof. Marcin Welnicki
(Egypt) (Poland)
GUIDELINES AND REVIEWS
2024 ESC Guidelines for the management of chronic coronary syndromes.
Vrints C, et al. Eur Heart J. 2024 Aug 30:ehae177. doi: 10.1093/eurheartj/ehae177. Online ahead of print.
The European Society of Cardiology have updated their clinical guidelines for the management of chronic coronary syndromes
(CCS). These guidelines update and replace the previous version from 2019 and partly replace the myocardial revascularisation
guidelines from 2018. They outline a stepwise approach to the diagnosis and treatment of CCS, a spectrum of heart conditions
caused by narrowing or blockage of the coronary arteries.
